Switch to:
Also traded in: Argentina, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.79
BMY's Cash-to-Debt is ranked lower than
65% of the 827 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.89 vs. BMY: 0.79 )
Ranked among companies with meaningful Cash-to-Debt only.
BMY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.32  Med: 0.97 Max: 3.88
Current: 0.79
0.32
3.88
Equity-to-Asset 0.44
BMY's Equity-to-Asset is ranked lower than
75% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. BMY: 0.44 )
Ranked among companies with meaningful Equity-to-Asset only.
BMY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.46 Max: 0.64
Current: 0.44
0.33
0.64
Debt-to-Equity 0.56
BMY's Debt-to-Equity is ranked lower than
69% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.30 vs. BMY: 0.56 )
Ranked among companies with meaningful Debt-to-Equity only.
BMY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.08  Med: 0.38 Max: 1.01
Current: 0.56
0.08
1.01
Debt-to-EBITDA 1.23
BMY's Debt-to-EBITDA is ranked higher than
60% of the 503 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.74 vs. BMY: 1.23 )
Ranked among companies with meaningful Debt-to-EBITDA only.
BMY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.71  Med: 1.22 Max: 2.57
Current: 1.23
0.71
2.57
Interest Coverage 24.57
BMY's Interest Coverage is ranked lower than
61% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 106.84 vs. BMY: 24.57 )
Ranked among companies with meaningful Interest Coverage only.
BMY' s Interest Coverage Range Over the Past 10 Years
Min: 8.03  Med: 15.49 Max: 45.84
Current: 24.57
8.03
45.84
Piotroski F-Score: 7
Altman Z-Score: 6.17
Beneish M-Score: -2.73
WACC vs ROIC
8.48%
20.32%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 21.73
BMY's Operating Margin % is ranked higher than
84% of the 781 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.94 vs. BMY: 21.73 )
Ranked among companies with meaningful Operating Margin % only.
BMY' s Operating Margin % Range Over the Past 10 Years
Min: 11.41  Med: 21.37 Max: 31.29
Current: 21.73
11.41
31.29
Net Margin % 22.66
BMY's Net Margin % is ranked higher than
89% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.12 vs. BMY: 22.66 )
Ranked among companies with meaningful Net Margin % only.
BMY' s Net Margin % Range Over the Past 10 Years
Min: 9.45  Med: 15.78 Max: 56.42
Current: 22.66
9.45
56.42
ROE % 30.24
BMY's ROE % is ranked higher than
93% of the 803 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.08 vs. BMY: 30.24 )
Ranked among companies with meaningful ROE % only.
BMY' s ROE % Range Over the Past 10 Years
Min: 10.75  Med: 20.69 Max: 78.36
Current: 30.24
10.75
78.36
ROA % 13.76
BMY's ROA % is ranked higher than
86% of the 831 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.77 vs. BMY: 13.76 )
Ranked among companies with meaningful ROA % only.
BMY' s ROA % Range Over the Past 10 Years
Min: 4.78  Med: 9.18 Max: 35.08
Current: 13.76
4.78
35.08
ROC (Joel Greenblatt) % 123.21
BMY's ROC (Joel Greenblatt) % is ranked higher than
96% of the 817 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.08 vs. BMY: 123.21 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BMY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 45.71  Med: 72.1 Max: 155.17
Current: 123.21
45.71
155.17
3-Year Revenue Growth Rate 5.50
BMY's 3-Year Revenue Growth Rate is ranked higher than
51% of the 674 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. BMY: 5.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BMY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -8.4  Med: 3.1 Max: 11.8
Current: 5.5
-8.4
11.8
3-Year EBITDA Growth Rate 18.40
BMY's 3-Year EBITDA Growth Rate is ranked higher than
67% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.20 vs. BMY: 18.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BMY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -26  Med: 7.6 Max: 22.1
Current: 18.4
-26
22.1
3-Year EPS without NRI Growth Rate 19.80
BMY's 3-Year EPS without NRI Growth Rate is ranked higher than
70% of the 632 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. BMY: 19.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BMY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -22.9  Med: 5.9 Max: 30.7
Current: 19.8
-22.9
30.7
GuruFocus has detected 7 Warning Signs with Bristol-Myers Squibb Company BMY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BMY's 30-Y Financials

Financials (Next Earnings Date: 2017-10-26)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

BMY Guru Trades in Q4 2016

David Tepper 375,000 sh (New)
Jeremy Grantham 3,500 sh (New)
Manning & Napier Advisors, Inc 3,060,280 sh (New)
Jana Partners 3,872,261 sh (New)
Dodge & Cox 22,532,761 sh (+31213.77%)
Vanguard Health Care Fund 51,340,697 sh (+5.20%)
Mairs and Power 340,822 sh (+3.02%)
T Rowe Price Equity Income Fund 3,125,000 sh (+0.81%)
Ken Fisher 653,730 sh (+0.52%)
First Eagle Investment 11,529 sh (unchged)
Kahn Brothers 28,583 sh (unchged)
Tom Gayner 10,000 sh (unchged)
Jeff Auxier 4,693 sh (unchged)
Julian Robertson Sold Out
Ron Baron Sold Out
Joel Greenblatt Sold Out
Ray Dalio Sold Out
Pioneer Investments 110,498 sh (-0.10%)
Ronald Muhlenkamp 178,961 sh (-0.75%)
Mario Gabelli 523,672 sh (-5.97%)
Murray Stahl 52,592 sh (-6.63%)
Paul Tudor Jones 23,777 sh (-79.66%)
Jim Simons 597,000 sh (-87.41%)
Eaton Vance Worldwide Health Sciences Fund 721,457 sh (-24.52%)
» More
Q1 2017

BMY Guru Trades in Q1 2017

Joel Greenblatt 10,061 sh (New)
PRIMECAP Management 1,772,900 sh (New)
Steven Cohen 152,500 sh (New)
Ray Dalio 96,670 sh (New)
Frank Sands 17,124 sh (New)
Jim Simons 6,468,000 sh (+983.42%)
Jeff Auxier 7,393 sh (+57.53%)
Dodge & Cox 29,120,190 sh (+29.23%)
T Rowe Price Equity Income Fund 3,750,000 sh (+20.00%)
Manning & Napier Advisors, Inc 3,236,578 sh (+5.76%)
Vanguard Health Care Fund 52,795,017 sh (+2.83%)
Ken Fisher 666,264 sh (+1.92%)
Mairs and Power 344,280 sh (+1.01%)
First Eagle Investment 11,529 sh (unchged)
Kahn Brothers 28,583 sh (unchged)
Tom Gayner 10,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 721,457 sh (unchged)
David Tepper Sold Out
Jeremy Grantham Sold Out
Ronald Muhlenkamp 178,201 sh (-0.42%)
Pioneer Investments 108,348 sh (-1.95%)
Mario Gabelli 513,047 sh (-2.03%)
Murray Stahl 48,607 sh (-7.58%)
Paul Tudor Jones 21,701 sh (-8.73%)
Signature Select Canadian Fund 118,750 sh (-25.99%)
Jana Partners 716,389 sh (-81.50%)
» More
Q2 2017

BMY Guru Trades in Q2 2017

Louis Moore Bacon 110,820 sh (New)
Caxton Associates 6,600 sh (New)
Joel Greenblatt 87,459 sh (+769.29%)
Paul Tudor Jones 82,386 sh (+279.64%)
PRIMECAP Management 6,315,000 sh (+256.20%)
Jim Simons 13,488,200 sh (+108.54%)
Ray Dalio 131,064 sh (+35.58%)
Vanguard Health Care Fund 53,643,117 sh (+1.61%)
Dodge & Cox 29,579,461 sh (+1.58%)
Murray Stahl 48,990 sh (+0.79%)
Tom Gayner 10,000 sh (unchged)
Steven Cohen 200,000 sh (unchged)
Steven Cohen 500,000 sh (unchged)
Jana Partners Sold Out
Ronald Muhlenkamp 177,974 sh (-0.13%)
Mairs and Power 343,043 sh (-0.36%)
First Eagle Investment 11,329 sh (-1.73%)
Frank Sands 16,774 sh (-2.04%)
T Rowe Price Equity Income Fund 3,670,300 sh (-2.13%)
Mario Gabelli 466,082 sh (-9.15%)
Jeff Auxier 6,393 sh (-13.53%)
Ken Fisher 507,027 sh (-23.90%)
Pioneer Investments 80,594 sh (-25.62%)
Kahn Brothers 19,583 sh (-31.49%)
Steven Cohen 100,000 sh (-34.43%)
Manning & Napier Advisors, Inc 2,034,602 sh (-37.14%)
Eaton Vance Worldwide Health Sciences Fund 645,201 sh (-10.57%)
» More
Q3 2017

BMY Guru Trades in Q3 2017

Spiros Segalas 9,730,165 sh (+20.11%)
T Rowe Price Equity Income Fund 3,165,000 sh (-13.77%)
» More
» Details

Insider Trades

Latest Guru Trades with BMY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
T Rowe Price Equity Income Fund 2017-09-30 Reduce -13.77%0.13%$54.24 - $63.74 $ 64.6711%3,165,000
Vanguard Health Care Fund 2017-06-30 Add 1.61%0.1%$51.66 - $57.33 $ 64.6719%53,643,117
Dodge & Cox 2017-06-30 Add 1.58%0.02%$51.66 - $57.33 $ 64.6719%29,579,461
T Rowe Price Equity Income Fund 2017-06-30 Reduce -2.13%0.02%$51.66 - $57.33 $ 64.6719%3,670,300
Ken Fisher 2017-06-30 Reduce -23.90%0.01%$51.66 - $57.33 $ 64.6719%507,027
Mario Gabelli 2017-06-30 Reduce -9.15%0.02%$51.66 - $57.33 $ 64.6719%466,082
Ronald Muhlenkamp 2017-06-30 Reduce -0.13%$51.66 - $57.33 $ 64.6719%177,974
Joel Greenblatt 2017-06-30 Add 769.29%0.06%$51.66 - $57.33 $ 64.6719%87,459
Kahn Brothers 2017-06-30 Reduce -31.49%0.09%$51.66 - $57.33 $ 64.6719%19,583
First Eagle Investment 2017-06-30 Reduce -1.73%$51.66 - $57.33 $ 64.6719%11,329
Vanguard Health Care Fund 2017-03-31 Add 2.83%0.18%$46.82 - $60.13 $ 64.6718%52,795,017
Dodge & Cox 2017-03-31 Add 29.23%0.31%$46.82 - $60.13 $ 64.6718%29,120,190
T Rowe Price Equity Income Fund 2017-03-31 Add 20.00%0.16%$46.82 - $60.13 $ 64.6718%3,750,000
Ken Fisher 2017-03-31 Add 1.92%$46.82 - $60.13 $ 64.6718%666,264
Mario Gabelli 2017-03-31 Reduce -2.03%$46.82 - $60.13 $ 64.6718%513,047
Ronald Muhlenkamp 2017-03-31 Reduce -0.42%0.01%$46.82 - $60.13 $ 64.6718%178,201
Joel Greenblatt 2017-03-31 New Buy0.01%$46.82 - $60.13 $ 64.6718%10,061
David Tepper 2017-03-31 Sold Out 0.39%$46.82 - $60.13 $ 64.6718%0
Vanguard Health Care Fund 2016-12-31 Add 5.20%0.35%$49.23 - $59.61 $ 64.6718%51,340,697
Dodge & Cox 2016-12-31 Add 31213.77%1.17%$49.23 - $59.61 $ 64.6718%22,532,761
T Rowe Price Equity Income Fund 2016-12-31 Add 0.81%0.01%$49.23 - $59.61 $ 64.6718%3,125,000
Ken Fisher 2016-12-31 Add 0.52%$49.23 - $59.61 $ 64.6718%653,730
Mario Gabelli 2016-12-31 Reduce -5.97%0.01%$49.23 - $59.61 $ 64.6718%523,672
David Tepper 2016-12-31 New Buy0.39%$49.23 - $59.61 $ 64.6718%375,000
Ronald Muhlenkamp 2016-12-31 Reduce -0.75%0.03%$49.23 - $59.61 $ 64.6718%178,961
Ron Baron 2016-12-31 Sold Out 0.01%$49.23 - $59.61 $ 64.6718%0
Julian Robertson 2016-12-31 Sold Out 5.11%$49.23 - $59.61 $ 64.6718%0
Joel Greenblatt 2016-12-31 Sold Out 0.06%$49.23 - $59.61 $ 64.6718%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Bristol-Myers Squibb Company

SymbolPriceYieldDescription
BMYMP1050.000.19$2.00 Convertible Preferred Stock

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:LSE:GSK, XTER:BAYN, NYSE:LLY, LSE:AZN, XPAR:SAN, NYSE:ABBV, NYSE:MRK, TSE:4503, TSE:4519, TSE:4578, TSE:4568, TSE:4528, HKSE:01093, MIL:REC, TSE:4151, BOM:500087, BOM:500302, XSWX:NOVN, TSE:4536, ISX:KLBF » details
Traded in other countries:BMY.Argentina, BMYB34.Brazil, BRM.Germany, BMY.Mexico, BMY.Switzerland, 0R1F.UK,
Headquarter Location:USA
Bristol-Myers Squibb Co is engaged in discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals and nutritional products. The company operates in two segments namely Pharmaceuticals and Nutritionals.

Bristol-Myers Squibb discovers, develops, and markets drugs for various indications, such as cardiovascular and infectious diseases, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded drugs.

Guru Investment Theses on Bristol-Myers Squibb Company

Baron Funds' Fifth Avenue Growth Fund Comments on Bristol-Myers Squibb Company - Feb 13, 2017

Bristol-Myers Squibb Company (NYSE:BMY) is a leading developer in Immuno-Oncology, the new wave of therapeutics aimed at displacing chemotherapeutics in cancer care with both improved efficacy (measured via survival outcomes) and safety profiles. While the class as a whole represents a success for society, the race for class dominance is heated and has proven to be difficult to predict. Coming into mid-2016, Bristol was the clear leader. The company squandered this lead in July when a widely anticipated clinical trial whose outcome was expected to read out positively, failed. While few question the drug’s efficacy, statistics and poor clinical trial design submarined Bristol and allowed competitor Merck to take the pole position commercially. Given the dire need for this patient population, the FDA granted Merck a pathway to market by the first half of this year that will give Merck at least a one year commercial advantage in time to market versus its competition. As a result, we decided to exit our investment in Bristol. While Merck has become the consensus leader, we think that their combination employs the wrong science approach and that Bristol is one of two players (AstraZeneca, the other) that will have an opportunity to ultimately come out on top given its strategy of combining two immune-therapeutics. We intend to follow the situation closely while looking for a more appropriate time to potentially get back into the investment.



From Baron Funds' Fifth Avenue Growth Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Dodge & Cox Comments on Bristol-Myers Squibb - Feb 01, 2017

Once a diversified pharmaceutical company facing significant patent expirations (a “cliff”), Bristol-Myers (NYSE:BMY) has transitioned into a focused biopharmaceutical company that is positioned to grow. Many of its competitors responded to their patent cliffs by expanding into other non-drug areas; Bristol-Myers shed its interests in those assets unrelated to the drug business (e.g., medical supply, nutritionals), focused on specialty drugs, and concentrated on only those therapeutic areas that it believed could be profitable over the long term. Its medicines help millions of people fight against such diseases as cancer, cardiovascular disease, hepatitis, HIV/ AIDS, and rheumatoid arthritis.



In 2016, one of Bristol-Myers’ lead immuno-oncology trials (CheckMate-026) failed and its stock price declined significantly. We think this is a short-term setback, and believe the company’s immuno-oncology business is particularly attractive with its strong pipeline of other drugs, significant growth potential, and reasonable valuation at 20 times forward earnings. After weighing the risks versus the long-term opportunities, we initiated a position in Bristol-Myers, which accounted for 1.3% of the Fund on December 31.





From Dodge & Cox's Stock Fund 2016 shareholder letter.



Check out Dodge & Cox latest stock trades

Baron Funds Comments on Bristol-Myers Squibb Co. - Oct 25, 2016

Bristol-Myers Squibb Company (NYSE:BMY) is a large diversified pharmaceutical company that is one of the leaders in the development of immune-system-stimulating therapies to fight cancer. These efforts are spearheaded by its product Opdivo, now approved to treat several types of cancer. After positive data was released on a rival drug to treat first-line advanced non-small-cell lung cancer, Bristol-Myers revealed that Opdivo did not meet the primary endpoint in a Phase III trial in the same indication, and its shares fell. We have exited our Bristol-Myers position, but are continuing to research the budding immuno-oncology space carefully. (Josh Riegelhaupt)







From Baron Opportunity Fund third-quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Bristol-Myers Squibb - May 23, 2016

After watching and following Bristol-Myers Squibb (NYSE:BMY) for the better part of the last three years we used the weakness in the stock created by the sell-off in the biotech sector to finally initiate a small to medium size position. Bristol specializes in small molecule drugs known as biologics, which are harder for the generic drug companies to replicate, and we are particularly excited about its lead immuno-oncology asset, Opdivo which has shown incredible promise in the treatment of lung cancer, while growing 10-20% month over month since its approval in 2015. Based on our belief in the effectiveness of the PD-1 class drugs, we think there is a high likelihood that Bristol will be able to gain approvals and expand the usage of Opdivo in other types of cancers (melanoma, renal, head and neck, hodgkin’s lymphoma, etc.) and could potentially change the paradigm of cancer’s treatment worldwide.



From Baron Fifth Avenue Growth Fund first quarter commentary 2016.



Check out Ron Baron latest stock trades

Baron Funds Comments on Bristol-Myers Squibb Company - May 06, 2016

After initiating a position in Bristol-Myers Squibb Company (NYSE:BMY), we increased our conviction in BMY’s stature as one of the premier names in all of biotech/pharma, deserving of its high multiple. Confidence comes from the performance of its lead immune-oncology asset, Opdivo that has captured 80–85% market share versus Merck’s competitive asset Keytruda, while growing 10–20% month over month. Given the frenetic pace of growth, we expect Opdivo to easily beat 2016’s $2.1 billion Consensus sales number. Looking past 2016, we expect this trend to continue as Bristol launches and/or expands usage of Opdivo in a variety of cancers (lung, melanoma, renal, head and neck, hodgkin’s lymphoma, etc.) and helps change the paradigm of cancer’s treatment worldwide.





From Baron Opportunity Fund first quarter 2016 commentary.







Check out Ron Baron latest stock trades

Top Ranked Articles about Bristol-Myers Squibb Company

Bristol-Myers Squibb (BMY) Extends Strategic Partnership with TARGET PharmaSolutions for TARGET-NASH
AbbVie and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors
2 Important Dates for Big Pharma Big PDUFA dates to watch for at the end of September
The last couple weeks of September are set to be big ones for two of the most well-known and largest (from a market capitalization perspective) companies in the biotechnology and health care spaces. Read more...
Halozyme Up After Cancer Deal, Markets Down Stock soars on deal with Bristol-Myers Squibb
U.S. stock market indexes opened lower on Thursday. Futures for the Dow Jones Industrial Average declined 3 points to 22,109. The Standard & Poor’s 500 index futures lost 2 points to 2,493 and futures for the Nasdaq 100 index declined 7 points to 6,002. The dollar index is down 0.06% at 92.35, while the U.S. 10-year bond yields 2.206% and the German 10-year bond yields 0.415%. Read more...
Stock Score Reports for Bristol-Myers Squibb, Cliffs Natural Resources, Hertz Global Holdings, Nordstrom and Oclaro Inc.
3 Stocks Soaring Today Big moves on positive news
The U.S. stock market opened slightly higher, with President Trump making a deal on Hurricane Harvey relief with Democrats, but closed mixed with only the Nasdaq in green. Ahead of that, three stocks have interesting upside movements. Read more...
Weekly Top Insider Buys Highlight for the Week of August 4 The largest Insider Buys were for AbbVie Inc., Bristol-Myers Squibb Co., General Motors Co. and Kinder Morgan Inc.
The largest Insider Buys this week were for AbbVie Inc. (NYSE:ABBV), Bristol-Myers Squibb Company (NYSE:BMY), General Motors Co. (NYSE:GM) and Kinder Morgan Inc. (NYSE:KMI). Read more...
Vanguard Health Care Fund Adds to Multiple Positions The fund built up many positions in the 2nd quarter
The Vanguard Health Care Fund (Trades, Portfolio) increased its holdings of many stocks during the quarter. The eight largest are as follows. Read more...
InvestorsObserver releases covered-call reports for Amazon.com, Bristol-Myers Squibb, Celgene, PayPal Holdings Inc. and Twitter
Biogen Increases Revenue Guidance in 2nd Quarter Company reports solid revenue growth, completes agreement with Bristol-Myers Squibb
Biogen Inc. (NASDAQ:BIIB), a Cambridge, Massachusetts-based biotech company, reported continued success in its long-term company strategies during the quarter ending June 30. Read more...

Ratios

vs
industry
vs
history
PE Ratio 23.51
BMY's PE Ratio is ranked higher than
56% of the 570 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.41 vs. BMY: 23.51 )
Ranked among companies with meaningful PE Ratio only.
BMY' s PE Ratio Range Over the Past 10 Years
Min: 4.09  Med: 23.04 Max: 77.61
Current: 23.51
4.09
77.61
Forward PE Ratio 20.24
BMY's Forward PE Ratio is ranked lower than
53% of the 74 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.53 vs. BMY: 20.24 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 23.51
BMY's PE Ratio without NRI is ranked higher than
57% of the 566 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.56 vs. BMY: 23.51 )
Ranked among companies with meaningful PE Ratio without NRI only.
BMY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.33  Med: 23.34 Max: 77.61
Current: 23.51
12.33
77.61
Price-to-Owner-Earnings 25.50
BMY's Price-to-Owner-Earnings is ranked higher than
64% of the 310 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.43 vs. BMY: 25.50 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BMY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.57  Med: 24.96 Max: 842.8
Current: 25.5
3.57
842.8
PB Ratio 7.22
BMY's PB Ratio is ranked lower than
85% of the 798 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.86 vs. BMY: 7.22 )
Ranked among companies with meaningful PB Ratio only.
BMY' s PB Ratio Range Over the Past 10 Years
Min: 2.46  Med: 5 Max: 8.51
Current: 7.22
2.46
8.51
PS Ratio 5.36
BMY's PS Ratio is ranked lower than
68% of the 756 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.79 vs. BMY: 5.36 )
Ranked among companies with meaningful PS Ratio only.
BMY' s PS Ratio Range Over the Past 10 Years
Min: 1.62  Med: 3.27 Max: 7.25
Current: 5.36
1.62
7.25
Price-to-Free-Cash-Flow 28.13
BMY's Price-to-Free-Cash-Flow is ranked lower than
54% of the 212 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.72 vs. BMY: 28.13 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BMY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.45  Med: 20 Max: 2406
Current: 28.13
7.45
2406
Price-to-Operating-Cash-Flow 21.26
BMY's Price-to-Operating-Cash-Flow is ranked lower than
56% of the 290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.64 vs. BMY: 21.26 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BMY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.96  Med: 14.63 Max: 124.02
Current: 21.26
6.96
124.02
EV-to-EBIT 17.76
BMY's EV-to-EBIT is ranked higher than
57% of the 572 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.28 vs. BMY: 17.76 )
Ranked among companies with meaningful EV-to-EBIT only.
BMY' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.2  Med: 16.2 Max: 126.7
Current: 17.76
6.2
126.7
EV-to-EBITDA 16.11
BMY's EV-to-EBITDA is ranked higher than
53% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.61 vs. BMY: 16.11 )
Ranked among companies with meaningful EV-to-EBITDA only.
BMY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.5  Med: 14.2 Max: 57.3
Current: 16.11
5.5
57.3
EV-to-Revenue 5.35
BMY's EV-to-Revenue is ranked lower than
66% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.07 vs. BMY: 5.35 )
Ranked among companies with meaningful EV-to-Revenue only.
BMY' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.6  Med: 3.5 Max: 7.4
Current: 5.35
1.6
7.4
Shiller PE Ratio 27.93
BMY's Shiller PE Ratio is ranked higher than
65% of the 204 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.18 vs. BMY: 27.93 )
Ranked among companies with meaningful Shiller PE Ratio only.
BMY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 10.76  Med: 17.57 Max: 36.36
Current: 27.93
10.76
36.36
Current Ratio 1.59
BMY's Current Ratio is ranked lower than
69% of the 738 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.53 vs. BMY: 1.59 )
Ranked among companies with meaningful Current Ratio only.
BMY' s Current Ratio Range Over the Past 10 Years
Min: 1.13  Med: 1.67 Max: 2.35
Current: 1.59
1.13
2.35
Quick Ratio 1.42
BMY's Quick Ratio is ranked lower than
62% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.94 vs. BMY: 1.42 )
Ranked among companies with meaningful Quick Ratio only.
BMY' s Quick Ratio Range Over the Past 10 Years
Min: 0.93  Med: 1.39 Max: 2.06
Current: 1.42
0.93
2.06
Days Inventory 102.09
BMY's Days Inventory is ranked higher than
60% of the 729 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 120.98 vs. BMY: 102.09 )
Ranked among companies with meaningful Days Inventory only.
BMY' s Days Inventory Range Over the Past 10 Years
Min: 84.37  Med: 122.43 Max: 141.93
Current: 102.09
84.37
141.93
Days Sales Outstanding 76.09
BMY's Days Sales Outstanding is ranked lower than
51% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.92 vs. BMY: 76.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
BMY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 35.38  Med: 64.65 Max: 79.99
Current: 76.09
35.38
79.99
Days Payable 102.76
BMY's Days Payable is ranked higher than
70% of the 619 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 68.69 vs. BMY: 102.76 )
Ranked among companies with meaningful Days Payable only.
BMY' s Days Payable Range Over the Past 10 Years
Min: 84.65  Med: 141.65 Max: 230.86
Current: 102.76
84.65
230.86

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.41
BMY's Dividend Yield % is ranked higher than
72% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.58 vs. BMY: 2.41 )
Ranked among companies with meaningful Dividend Yield % only.
BMY' s Dividend Yield % Range Over the Past 10 Years
Min: 1.99  Med: 3.91 Max: 7.07
Current: 2.41
1.99
7.07
Dividend Payout Ratio 0.57
BMY's Dividend Payout Ratio is ranked lower than
76% of the 416 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. BMY: 0.57 )
Ranked among companies with meaningful Dividend Payout Ratio only.
BMY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.57  Med: 0.92 Max: 1.6
Current: 0.57
0.57
1.6
3-Year Dividend Growth Rate 2.80
BMY's 3-Year Dividend Growth Rate is ranked lower than
61% of the 303 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. BMY: 2.80 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
BMY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 3.1 Max: 14.2
Current: 2.8
0
14.2
Forward Dividend Yield % 2.45
BMY's Forward Dividend Yield % is ranked higher than
68% of the 679 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.05 vs. BMY: 2.45 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 2.77
BMY's 5-Year Yield-on-Cost % is ranked higher than
66% of the 849 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.98 vs. BMY: 2.77 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
BMY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.28  Med: 4.49 Max: 8.12
Current: 2.77
2.28
8.12
3-Year Average Share Buyback Ratio -0.50
BMY's 3-Year Average Share Buyback Ratio is ranked higher than
76% of the 522 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.80 vs. BMY: -0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BMY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.6  Med: 0.6 Max: 5.2
Current: -0.5
-0.6
5.2

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 16.09
BMY's Price-to-Tangible-Book is ranked lower than
92% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.49 vs. BMY: 16.09 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BMY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.16  Med: 12.06 Max: 53.46
Current: 16.09
4.16
53.46
Price-to-Intrinsic-Value-Projected-FCF 2.49
BMY's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
51% of the 306 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.32 vs. BMY: 2.49 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BMY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.13  Med: 1.77 Max: 4.89
Current: 2.49
1.13
4.89
Price-to-Median-PS-Value 1.63
BMY's Price-to-Median-PS-Value is ranked lower than
81% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.04 vs. BMY: 1.63 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BMY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.59  Med: 0.91 Max: 2.63
Current: 1.63
0.59
2.63
Price-to-Peter-Lynch-Fair-Value 2.31
BMY's Price-to-Peter-Lynch-Fair-Value is ranked lower than
68% of the 183 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.58 vs. BMY: 2.31 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
BMY' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.73  Med: 2.17 Max: 11.32
Current: 2.31
0.73
11.32
Price-to-Graham-Number 4.10
BMY's Price-to-Graham-Number is ranked lower than
81% of the 438 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.97 vs. BMY: 4.10 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BMY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.53  Med: 3.11 Max: 15.06
Current: 4.1
1.53
15.06
Earnings Yield (Greenblatt) % 5.64
BMY's Earnings Yield (Greenblatt) % is ranked higher than
71% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.23 vs. BMY: 5.64 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BMY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.8  Med: 6.2 Max: 16.1
Current: 5.64
0.8
16.1
Forward Rate of Return (Yacktman) % 13.08
BMY's Forward Rate of Return (Yacktman) % is ranked higher than
57% of the 397 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.07 vs. BMY: 13.08 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BMY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -15.1  Med: 3.5 Max: 26.7
Current: 13.08
-15.1
26.7

More Statistics

Revenue (TTM) (Mil) $20,238.00
EPS (TTM) $ 2.75
Beta1.10
Short Percentage of Float0.56%
52-Week Range $46.01 - 66.10
Shares Outstanding (Mil)1,639.93

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 20,297 21,368 22,842
EPS ($) 2.90 3.18 3.65
EPS without NRI ($) 2.90 3.18 3.65
EPS Growth Rate
(Future 3Y To 5Y Estimate)
13.03%
Dividends per Share ($) 1.58 1.67 1.66

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}